Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coreg CR Once-Daily Sustains Blood Pressure Reduction Over 24 Hours, Study Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

The controlled-release version of GlaxoSmithKline’s beta blocker carvedilol has an estimated user fee date of late October.

You may also be interested in...



Coreg CR Approved; GSK Plans First Quarter 2007 Launch

Micropump technology licensed from French drug delivery firm Flamel modulates release of GSK’s carvedilol over 24 hours.

Coreg CR Approved; GSK Plans First Quarter 2007 Launch

Micropump technology licensed from French drug delivery firm Flamel modulates release of GSK’s carvedilol over 24 hours.

GSK Urges Conservation Of Coreg, Citing Limited Availability

The company will release a "Dear Healthcare Provider" letter that identifies treatment options for patients with mild to moderate heart failure who cannot get their carvedilol prescriptions filled.

Topics

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel